Medindia

X

Reportlinker Adds Epilepsy - Drug Pipeline Analysis and Market Forecasts to 2015

Wednesday, December 16, 2009 Research News J E 4
Advertisement


NEW YORK, Dec. 15 Reportlinker.com announces that a new market research report is available in its catalogue:

Epilepsy - Drug Pipeline Analysis and Market Forecasts to 2015

http://www.reportlinker.com/p0167273/Epilepsy---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015.html

Epilepsy - Drug Pipeline Analysis and Market Forecasts to 2015

Summary

GlobalData, the industry analysis specialist's new report, "Epilepsy - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global epilepsy market. The report identifies the key trends shaping and driving the global epilepsy market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global epilepsy sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- Annualized global epilepsy market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.

- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action includes Voltage-gated ion channels (a2-d subunit of the voltage-gated Ca++ channel; the a subunits of voltage-gated Na+ channels; K+ channels); Enhancement of GABA-mediated transmissions, Acetylcholine agonists, NMDA targetters, Benzodiazepines.

- Analysis of the current and future market competition in the global epilepsy market. Key market players covered are Pfizer, UCB Pharma, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Abbott Laboratories, Sanofi-Aventis SA, and Cephalon.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with epilepsy.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global epilepsy market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global epilepsy market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global epilepsy market landscape? - Identify, understand and capitalize.

Table of Contents

1 Epilepsy Market: Executive Summary

1.1 The Epilepsy Market is Forecast to Show Low Market Potential to 2015

1.2 Most of the Pipeline Portfolio is Maintained by the Top Market Players

1.3 Current Market Partially Successful in Meeting Patients' Expectations

1.4 Me-too Drugs Contribute to a Strong Pipeline Structure

1.5 Unmet Need Continues to Remain Unaddressed

2 Table Of Contents

2.1 List of Tables

2.2 List of Figures

3 Epilepsy Market: Market Characterization

3.1 Overview

3.2 Epilepsy Market Size

3.3 Epilepsy Market Forecast and CAGR

3.4 Drivers and Barriers for the Epilepsy Market

3.4.1 Drivers for the Epilepsy Market

3.4.2 Barriers for the Epilepsy Market

3.5 Opportunity and Unmet Need

3.6 Key Takeaway

4 Epilepsy Market: Competitive Assessment

4.1 Overview

4.2 Strategic Competitor Assessment

4.3 Product Profile for the Major Marketed Products in the Epilepsy Market

4.3.1 Lyrica (Pregabalin)

4.3.1.1 Overview

4.3.1.2 Efficacy

4.3.1.3 Safety Profile

4.3.1.4 Pricing

4.3.1.5 Clinical Study Details

4.3.2 Gabitril (Tiagabine Hcl)

4.3.2.1 Overview

4.3.2.2 Efficacy

4.3.2.3 Safety Profile

4.3.2.4 Pricing

4.3.2.5 Clinical Study Details

4.3.3 Banzel (Rufinamide)

4.3.3.1 Overview

4.3.3.2 Efficacy

4.3.3.3 Safety Profile

4.3.3.4 Pricing

4.3.3.5 Clinical Study Details

4.3.4 Vimpat (Lacosamide)

4.3.4.1 Overview

4.3.4.2 Efficacy

4.3.4.3 Safety Profile

4.3.4.4 Pricing

4.3.4.5 Clinical Study Details

4.3.5 Felbatol (Felbamate)

4.3.5.1 Overview

4.3.5.2 Efficacy

4.3.5.3 Safety Profile

4.3.5.4 Pricing

4.3.5.5 Clinical Study Details

4.3.6 Sabril (Vigabatrin)

4.3.6.1 Overview

4.3.6.2 Efficacy

4.3.6.3 Safety Profile

4.3.6.4 Pricing

4.3.6.5 Clinical Study Details

4.4 Key Takeaway

5 Epilepsy Market: Pipeline Assessment

5.1 Overview

5.2 Strategic Pipeline Assessment

5.2.1 Technology Trends Analytic Framework

5.3 Epilepsy Therapeutics - Promising Drugs under Clinical Development

5.4 Molecule Profile for Promising Drugs under Clinical Development

5.4.1 Stedesa (Eslicarbazepine Acetate)

5.4.1.1 Overview

5.4.1.2 Efficacy

5.4.1.3 Safety Profile

5.4.1.4 Clinical Study Details

5.4.2 Comfyde(TM) (Carisbamate)

5.4.2.1 Overview

5.4.2.2 Efficacy

5.4.2.3 Safety Profile

5.4.2.4 Clinical Study Details

5.4.3 Retigabine

5.4.3.1 Overview

5.4.3.2 Efficacy

5.4.3.3 Safety Profile

5.4.3.4 Clinical Study Details

5.4.4 Brivaracetam

5.4.4.1 Overview

5.4.4.2 Efficacy

5.4.4.3 Safety Profile

5.4.4.4 Clinical Study Details

5.4.5 Ganaxolone

5.4.5.1 Overview

5.4.5.2 Efficacy

5.4.5.3 Safety Profile

5.4.5.4 Clinical Study Details

5.5 Epilepsy Therapeutics Market - Clinical Pipeline by Mechanism of Action

5.6 Epilepsy Pipeline - Pipeline by Clinical Phases of Development

5.6.1 Epilepsy Therapeutics - Regulatory and Phase III Clinical Pipeline

5.6.2 Epilepsy Therapeutics - Phase II Clinical Pipeline

5.6.3 Epilepsy Therapeutics - Phase I Clinical Pipeline

5.6.4 Epilepsy Therapeutics - Preclinical Pipeline

5.7 Discontinued / Suspended Drugs for Epilepsy

5.8 Key Takeaway

6 Epilepsy Market: Implications for Future Market Competition

7 Epilepsy Market: Future Players in the Epilepsy Market

7.1 Introduction

7.2 GlaxoSmithKline plc

7.2.1 Overview

7.2.2 CNS Portfolio

7.2.2.1 Marketed Products

7.2.2.2 Pipeline Products

7.2.3 Epilepsy Portfolio

7.2.3.1 Retigabine

7.2.3.2 Lamictal XR

7.3 UCB Pharmaceuticals

7.3.1 Overview

7.3.2 CNS Portfolio

7.3.2.1 Marketed Products

7.3.2.2 Pipeline Products

7.3.3 Epilepsy Product Portfolio

7.3.3.1 Brivaracetam

7.3.3.2 Keppra XR

7.4 Johnson & Johnson

7.4.1 Overview

7.4.2 CNS Portfolio

7.4.2.1 Marketed Products

7.4.2.2 Pipeline Products

7.4.3 Epilepsy Product Portfolio

7.4.3.1 COMFYDE (Carisbamate)

7.5 Pfizer Inc.

7.5.1 Overview

7.5.2 CNS Portfolio

7.5.2.1 Marketed Products

7.5.2.2 Pipeline Products

7.5.3 Epilepsy Product Portfolio

7.5.3.1 Lyrica

7.6 Sepracor Inc

7.6.1 Overview

7.6.2 CNS Portfolio

7.6.2.1 Marketed Products

7.6.2.2 Pipeline Products

7.6.3 Epilepsy Product Portfolio

7.6.3.1 Stedesa

7.7 Supernus Pharmaceuticals Inc

7.7.1 Overview

7.7.2 CNS Portfolio

7.7.2.1 Marketed Products

7.7.2.2 Pipeline Products

7.7.3 Epilepsy Product Portfolio

7.7.3.1 Epliga

7.7.3.2 Trokesa

7.7.3.3 SPN802

8 Epilepsy Market: Appendix

8.1 Definitions

8.2 Acronyms

8.3 Research Methodology

8.3.1 Coverage

8.3.2 Secondary Research

8.3.3 Forecasting

8.3.3.1 Epidemiology-based Forecasting

8.3.4 Primary Research

8.3.5 Expert Panel validation

8.4 Contact Us

8.5 Disclaimer

8.6 Sources

List of Tables

Table 1: Global Epilepsy Therapeutics Market, Revenue ($bn), 2000-2015

Table 2: Major Marketed Products Comparison in the Epilepsy Market, 2009

Table 3: Epilepsy Therapeutics - Most Promising Drugs Under Clinical Development, 2009

Table 4: Epilepsy Therapeutics - Phase III Clinical Pipeline, 2009

Table 5: Epilepsy Therapeutics - Phase II Clinical Pipeline, 2009

Table 6: Epilepsy Therapeutics - Phase I Clinical Pipeline, 2009

Table 7: Epilepsy Therapeutics - Preclinical Pipeline, 2009

Table 8: GlaxoSmithKline - CNS Marketed Products, 2009

Table 9: GlaxoSmithKline - CNS Pipeline Products, 2009

Table 10: UCB Pharma - CNS Marketed Products, 2009

Table 11: UCB Pharma - CNS Pipeline Products, 2009

Table 12: Johnson & Johnson - CNS Marketed Products, 2009

Table 13: Johnson & Johnson - CNS Pipeline Products, 2009

Table 14: Pfizer - CNS Marketed Products, 2009

Table 15: Pfizer - CNS Pipeline Products, 2009

Table 16: Sepracor Inc. - CNS Marketed Products, 2009

Table 17: Sepracor Inc. - CNS Pipeline Products, 2009

Table 18: Supernus Pharmaceuticals - CNS Pipeline Products, 2009

List of Figures

Figure 1: Global Epilepsy Market Revenue ($m) 2000-2015

Figure 2: Opportunity and Unmet Need, 2009

Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Epilepsy, 2009

Figure 4: Technology Trends Analytic Framework of the Epilepsy Pipeline, 2009

Figure 5: Technology Trends Analytic Framework of the Epilepsy Pipeline - Description, 2009

Figure 6: Epilepsy Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2009

Figure 7: Epilepsy Pipeline by Phase of Clinical Development, 2009

Figure 8: Implications for Future Market Competition in the Epilepsy Market, 2009

Figure 9: Epilepsy Therapeutics Market - Clinical Pipeline by Company, 2009

Figure 10: GlobalData Methodology

Figure 11: GlobalData Market Forecasting Model

Companies mentioned

Pfizer, Cephalon, Inc, Novo Nordisk, Abbott Laboratories, Novartis Pharma AG, Eisai Co. Ltd , UCB Inc, Schwarz Pharma, MedPointe Pharmaceuticals, Sanofi-Aventis, H. Lundbeck A/S , BIAL-Portela & Ca, S.A, Sepracor Inc., SK Bio Pharmaceuticals , Johnson & Johnson Pharmaceutical Research and Development, L.L.C, by Ortho-McNeil Neurologics, Valeant Pharmaceuticals , GlaxoSmithKline, Marinus Pharmaceuticals , Supernus Pharmaceuticals

To order this report:

Pharmaceutical Industry: Epilepsy - Drug Pipeline Analysis and Market Forecasts to 2015

More Market Research Report

Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Ovarian Cancer - Drug Pipeline A...
S
Reportlinker Adds the Future of e-Clinical Trial S...